Oroxylin A was shown to have a beneficial therapeutic effect on breast cancer by specifically binding to α-actinins 1 (ACTN1), thereby inhibiting ACTN1 expression to prevent cancer cell metastasis [92]. Here, ACTN1 is linked to breast cancer.